Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Professor Tedder stated he aimed to produce a competitive test that was one step instead of two.

  • Read more about Professor Tedder stated he aimed to produce a competitive test that was one step instead of two.

Professor Tedder stated that various UK HIV tests were available by mid July 1984. However, though these were in used in laboratories, there was little widespread knowledge of this at the time.

  • Read more about Professor Tedder stated that various UK HIV tests were available by mid July 1984. However, though these were in used in laboratories, there was little widespread knowledge of this at the time.

Dr Gunson reported that a HTLV-3 test produced by Dr Tedder and Professor Weiss would be available within the foreseeable future and the Blood Transfusion Service had agreed at a meeting with Dr Tedder that it would start appraisal of their test as soon as possible. Dr Gunson also anticipated that a major decision to proceed to routine screening of all blood would be required.

  • Read more about Dr Gunson reported that a HTLV-3 test produced by Dr Tedder and Professor Weiss would be available within the foreseeable future and the Blood Transfusion Service had agreed at a meeting with Dr Tedder that it would start appraisal of their test as soon as possible. Dr Gunson also anticipated that a major decision to proceed to routine screening of all blood would be required.

Professor Weiss wrote an article on AIDS in Nature, which stated that there was no longer any doubt that AIDS was caused by an infectious agent and emphasised that ELISA screening tests for blood supplies were "urgently needed".

  • Read more about Professor Weiss wrote an article on AIDS in Nature, which stated that there was no longer any doubt that AIDS was caused by an infectious agent and emphasised that ELISA screening tests for blood supplies were "urgently needed".

Five pharmaceutical companies in the US were chosen to manufacture AIDS blood tests.

  • Read more about Five pharmaceutical companies in the US were chosen to manufacture AIDS blood tests.

Following Professor Gallo's HTLV-3 press conference, the US Secretary of State for Health predicted there would be a test to screen blood widely available within six months.

  • Read more about Following Professor Gallo's HTLV-3 press conference, the US Secretary of State for Health predicted there would be a test to screen blood widely available within six months.

In a press conference, Professor Gallo termed the virus that caused AIDS "HTLV-III", despite evidence that it was an HTLV virus being tenuous.

  • Read more about In a press conference, Professor Gallo termed the virus that caused AIDS "HTLV-III", despite evidence that it was an HTLV virus being tenuous.

At a meeting of the ACVSB Group meeting it was stated that anti-HBc testing alone was insufficient to eradicate post-transfusion hepatitis.

  • Read more about At a meeting of the ACVSB Group meeting it was stated that anti-HBc testing alone was insufficient to eradicate post-transfusion hepatitis.

Dr Richard Aach commented on the report of the TTV study group: "the evidence was predictive rather than absolute - the same type of evidence that served as a basis for adoption of routine testing of donors for HBsAg in order to reduce Type B hepatitis transmission by transfusion".

  • Read more about Dr Richard Aach commented on the report of the TTV study group: "the evidence was predictive rather than absolute - the same type of evidence that served as a basis for adoption of routine testing of donors for HBsAg in order to reduce Type B hepatitis transmission by transfusion".

Alter et al published a paper titled 'The Chronic Sequelae of Non-A Non-B Hepatitis B' in the Annals of Internal Medicine journal.

  • Read more about Alter et al published a paper titled 'The Chronic Sequelae of Non-A Non-B Hepatitis B' in the Annals of Internal Medicine journal.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 687
  • Page 688
  • Page 689
  • Page 690
  • Current page 691
  • Page 692
  • Page 693
  • Page 694
  • Page 695
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.